{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T17:00:11Z","timestamp":1791910811415,"version":"4.3.4"},"reference-count":36,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2020,10,27]],"date-time":"2020-10-27T00:00:00Z","timestamp":1603756800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"DOI":"10.3389\/fneur.2020.594152","type":"journal-article","created":{"date-parts":[[2020,10,27]],"date-time":"2020-10-27T04:43:17Z","timestamp":1603773797000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":29,"title":["Favorable Effects of Tacrolimus Monotherapy on Myasthenia Gravis Patients"],"prefix":"10.3389","volume":"11","author":[{"given":"Zhirong","family":"Fan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zunbo","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faxiu","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xueping","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Lei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shengyao","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Di","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuwei","family":"Da","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2020,10,27]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1038\/s41572-019-0079-y","article-title":"Myasthenia gravis","volume":"5","author":"Gilhus","year":"2019","journal-title":"Nat Rev Dis Primers"},{"key":"B2","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1212\/WNL.0000000000002790","article-title":"International consensus guidance for management of myasthenia gravis: executive summary","volume":"87","author":"Sanders","year":"2016","journal-title":"Neurology"},{"key":"B3","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1111\/ane.12261","article-title":"Glucocorticoids in myasthenia gravis\u2014if, when, how, and how much?","volume":"130","author":"Hoffmann","year":"2014","journal-title":"Acta Neurol Scand"},{"key":"B4","doi-asserted-by":"publisher","first-page":"2216","DOI":"10.1016\/j.clinthera.2017.09.011","article-title":"Long-term systemic corticosteroid exposure: a systematic literature review","volume":"39","author":"Rice","year":"2017","journal-title":"Clin Ther"},{"key":"B5","doi-asserted-by":"publisher","first-page":"239","DOI":"10.3109\/10673229809000307","article-title":"Mood symptoms during corticosteroid therapy: a review","volume":"5","author":"Brown","year":"1998","journal-title":"Harv Rev Psychiatry"},{"key":"B6","doi-asserted-by":"publisher","first-page":"CD005224","DOI":"10.1002\/14651858.CD005224.pub2","article-title":"Immunosuppressive agents for myasthenia gravis","volume":"4","author":"Hart","year":"2007","journal-title":"Cochrane Database Syst Rev"},{"key":"B7","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1002\/ana.410150615","article-title":"Azathioprine in the treatment of myasthenia gravis","volume":"15","author":"Witte","year":"1984","journal-title":"Ann Neurol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1438","DOI":"10.1212\/01.wnl.0000094122.88929.0b","article-title":"Mycophenolate mofetil for myasthenia gravis: an analysis of efficacy, safety, and tolerability","volume":"61","author":"Meriggioli","year":"2003","journal-title":"Neurology"},{"key":"B9","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1186\/1471-2377-11-97","article-title":"A single-blinded trial of methotrexate vs. azathioprine as steroid-sparing agents in generalized myasthenia gravis","volume":"11","author":"Heckmann","year":"2011","journal-title":"BMC Neurol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1212\/wnl.55.3.448","article-title":"Retrospective analysis of the use of cyclosporine in myasthenia gravis","volume":"55","author":"Ciafaloni","year":"2000","journal-title":"Neurology"},{"key":"B11","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1097\/FPC.0b013e328364db84","article-title":"PharmGKB summary: cyclosporine and tacrolimus pathways","volume":"23","author":"Barbarino","year":"2013","journal-title":"Pharmacogenet Genomics"},{"key":"B12","doi-asserted-by":"publisher","first-page":"481","DOI":"10.2215\/CJN.04800908","article-title":"Calcineurin inhibitor nephrotoxicity","volume":"4","author":"Naesens","year":"2009","journal-title":"Clin J Am Soc Nephrol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1002\/mus.10472","article-title":"Clinical study of FK506 in patients with myasthenia gravis","volume":"28","author":"Konishi","year":"2003","journal-title":"Muscle Nerve"},{"key":"B14","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1007\/s10072-016-2769-5","article-title":"Long-term efficacy and side effects of low-dose tacrolimus for the treatment of myasthenia gravis","volume":"38","author":"Tao","year":"2017","journal-title":"Neurol Sci"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1185\/030079904125004385","article-title":"Low-dose tacrolimus treatment in thymectomised and steroid-dependent myasthenia gravis","volume":"20","author":"Kawaguchi","year":"2004","journal-title":"Curr Med Res Opin"},{"key":"B16","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1111\/nyas.13544","article-title":"Rationale for the clinical guidelines for myasthenia gravis in Japan","volume":"1413","author":"Murai","year":"2018","journal-title":"Ann N Y Acad Sci"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1007\/s00415-016-8045-z","article-title":"Clinical features, pathogenesis, and treatment of myasthenia gravis: a supplement to the Guidelines of the German Neurological Society","volume":"263","author":"Melzer","year":"2016","journal-title":"J Neurol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1159\/000347068","article-title":"Tacrolimus monotherapy: a promising option for ocular myasthenia gravis","volume":"69","author":"Yagi","year":"2013","journal-title":"Eur Neurol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1056\/NEJM198703193161205","article-title":"Preliminary results of a double-blind, randomized, placebo-controlled trial of cyclosporine in myasthenia gravis","volume":"316","author":"Tindall","year":"1987","journal-title":"N Engl J Med"},{"key":"B20","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1111\/j.1749-6632.1993.tb22937.x","article-title":"A clinical therapeutic trial of cyclosporine in myasthenia gravis","volume":"681","author":"Tindall","year":"1993","journal-title":"Ann N Y Acad Sci"},{"key":"B21","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1111\/ene.13189","article-title":"Adequate tacrolimus concentration for myasthenia gravis treatment","volume":"24","author":"Kanai","year":"2017","journal-title":"Eur J Neurol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1136\/jnnp-2011-300148","article-title":"Randomised, double-blind, placebo-controlled study of tacrolimus in myasthenia gravis","volume":"82","author":"Yoshikawa","year":"2011","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"B23","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/j.intimp.2010.12.012","article-title":"Clinical efficacy and immunological impact of tacrolimus in Chinese patients with generalized myasthenia gravis","volume":"11","author":"Zhao","year":"2011","journal-title":"Int Immunopharmacol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/s0303-8467(03)00046-5","article-title":"Tacrolimus hydrate (FK506): therapeutic effects and selection of responders in the treatment of myasthenia gravis","volume":"106","author":"Wakata","year":"2003","journal-title":"Clin Neurol Neurosurg"},{"key":"B25","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1002\/mus.21462","article-title":"Factors associated with response to calcineurin inhibitors in myasthenia gravis","volume":"41","author":"Nagane","year":"2010","journal-title":"Muscle Nerve"},{"key":"B26","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1002\/ana.410060107","article-title":"Pupillary dysfunction in myasthenia gravis","volume":"6","author":"Lepore","year":"1979","journal-title":"Ann Neurol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/S0065-2423(08)60274-7","article-title":"Dynamic pupillographic response to positive differential light stimulation in myasthenia gravis","volume":"98","author":"Lu","year":"1985","journal-title":"Chin Med J"},{"key":"B28","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.physbeh.2016.12.010","article-title":"Anticholinergic activity in the nervous system: consequences for visuomotor function","volume":"170","author":"Naicker","year":"2017","journal-title":"Physiol Behav"},{"key":"B29","doi-asserted-by":"publisher","first-page":"242","DOI":"10.4103\/1673-5374.290880","article-title":"Possible implications of dysregulated nicotinic acetylcholine receptor diffusion and nanocluster formation in myasthenia gravis","volume":"16","author":"Barrantes","year":"2021","journal-title":"Neural Regen Res"},{"key":"B30","doi-asserted-by":"publisher","first-page":"86","DOI":"10.3389\/fnmol.2020.00086","article-title":"Myasthenia gravis: from the viewpoint of pathogenicity focusing on acetylcholine receptor clustering, trans-synaptic homeostasis and synaptic stability","volume":"13","author":"Takamori","year":"2020","journal-title":"Front Mol Neurosci"},{"key":"B31","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1007\/s11910-018-0864-0","article-title":"Photophobia: when light hurts, a review","volume":"18","author":"Albilali","year":"2018","journal-title":"Curr Neurol Neurosci Rep"},{"key":"B32","doi-asserted-by":"publisher","first-page":"633","DOI":"10.3349\/ymj.2019.60.7.633","article-title":"Long-term safety and efficacy of tacrolimus in myasthenia gravis","volume":"60","author":"Kim","year":"2019","journal-title":"Yonsei Med J"},{"key":"B33","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1177\/1756285617721092","article-title":"Tacrolimus in the treatment of myasthenia gravis in patients with an inadequate response to glucocorticoid therapy: randomized, double-blind, placebo-controlled study conducted in China","volume":"10","author":"Zhou","year":"2017","journal-title":"Ther Adv Neurol Disord"},{"key":"B34","doi-asserted-by":"publisher","first-page":"2301","DOI":"10.1111\/ajt.13309","article-title":"Pharmacokinetics and toxicity of tacrolimus early after heart and lung transplantation","volume":"15","author":"Sikma","year":"2015","journal-title":"Am J Transplant"},{"key":"B35","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1007\/s001470000285","article-title":"Calcineurin-inhibitor induced pain syndrome (CIPS): a severe disabling complication after organ transplantation","volume":"14","author":"Grotz","year":"2001","journal-title":"Transpl Int"},{"key":"B36","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1038\/sj.ki.5001833","article-title":"Calcineurin-inhibitor induced pain syndrome after organ transplantation","volume":"70","author":"Collini","year":"2006","journal-title":"Kidney Int"}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2020.594152\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,27]],"date-time":"2020-10-27T04:43:20Z","timestamp":1603773800000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2020.594152\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,27]]},"references-count":36,"alternative-id":["10.3389\/fneur.2020.594152"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2020.594152","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,27]]},"article-number":"594152"}}